[New possibilities of pharmacotherapy of epilepsy: eslicarbazepine acetate in treatment of focal epilepsy].  The article provides an analysis of the latest antiepileptic drug eslicarbazepine acetate (ESL) for the treatment of focal epilepsy in adults as monotherapy and adjunctive therapy.
Pharmacokinetics, pharmacodynamics, drug-drug interactions, indications and dosage regimen are described.  The authors present the latest data on the efficacy, tolerability and safety of ESL including an exploratory pooled analysis of data from 14 European clinical practice studies (Euro-Esli) as well as their own observations of 34 patients receiving ESL in monotherapy or combination therapy.
